Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1082250

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Parkinson’s disease is the second most common neurological disease in Australia, yet there is no treatment to slow disease progression. Our study is investigating inflammation within the brain as a major contributing factor in Parkinson’s disease. We will examine this inflammatory pathway in human patients suffering from Parkinson’s, and will test a novel anti-inflammatory drug in animal models of Parkinson’s disease, in order to identify a novel treatment to reduce disease pathology.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $497,941.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Central Nervous System

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Parkinson disease | complement C5a | microglia | neuroinflammation | therapeutic target

Related Links